Effects of a novel hepatitis B anti-viral drug E-CFCP in renal organic acid transporters

• Päätekijät: Misaki Ishibane (Tekijä), Hirofumi Hashimoto (Tekijä), Meika Kaneko (Tekijä), Shota Saito (Tekijä), Sangjon Pae (Tekijä), Shinpei Saito (Tekijä), Yoshie Reien (Tekijä), Yuri Hirayama (Tekijä), Nobuyo Higashi-Kuwata (Tekijä), Hiroaki Mitsuya (Tekijä), Naohiko Anzai (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Elsevier, 2022-12-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Currently, the emergence of drug resistance is an important issue in the treatment of hepatitis B virus (HBV). Recently, our collaborating group developed a novel long-acting anti-HBV drug, E-CFCP. However, until this study, the effects of E-CFCP in the kidney have remained unclarified. Using cell v...